PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2686903-5 1989 We thus found that MD805 could be used as an anticoagulant drug when an AT III-deficient patient required anticoagulation in the extracorporeal circulation. argatroban 19-24 serpin family C member 1 Homo sapiens 72-78 33390937-11 2020 This study is the first report of administering argatroban and titrating to its appropriate dose in the patient with valve thrombosis, antithrombin deficiency, and HT after mechanical thrombectomy for acute ischemic stroke. argatroban 48-58 serpin family C member 1 Homo sapiens 135-147 16293985-6 2005 However, the complete loss of thrombin-induced VEGF production upon treatment with argatroban, a derivative of arginine and a potent anticoagulant/antithrombin agent, supports the notion that argatroban serves as a useful therapeutic tool for thrombin-associated pathologic conditions. argatroban 83-93 serpin family C member 1 Homo sapiens 147-159 31894660-2 2020 Guidance for laboratory testing to diagnose antithrombin deficiency include the use of an activity assay for initial testing, performing an antigen test and activity-to-antigen ratio when the activity level is low, using pediatric reference ranges until the age of 6 months, excluding acquired causes of low antithrombin (e.g. liver dysfunction, proteinuria, heparin, disseminated intravascular coagulation, thrombosis, surgery) or falsely normal/elevated results (e.g. argatroban, bivalirudin, dabigatran in factor IIa-based assays; rivaroxaban, apixaban, edoxaban, but not betrixaban in Xa-based assays). argatroban 470-480 serpin family C member 1 Homo sapiens 44-56 18560242-1 2008 BACKGROUND/AIMS: Argatroban, a hepatically metabolized direct thrombin inhibitor, is approved for use in heparin-induced thrombocytopenia (HIT; several countries) and in antithrombin-deficient patients undergoing hemodialysis (Japan). argatroban 17-27 serpin family C member 1 Homo sapiens 170-182 18560242-3 2008 METHODS: A literature search identified 34 publications (12 prospective studies, 4 retrospective studies, 18 anecdotal reports) that together described 644 argatroban-treated patients (446 with HIT, 82 with antithrombin deficiency) with varying degrees of renal function. argatroban 156-166 serpin family C member 1 Homo sapiens 207-219 18560242-9 2008 CONCLUSION: Current literature suggests that argatroban is well tolerated and provides adequate anticoagulation in patients with renal dysfunction or failure, including individuals with HIT or antithrombin deficiency where anticoagulant options are limited. argatroban 45-55 serpin family C member 1 Homo sapiens 193-205 25594496-2 2015 The aim of this study was to investigate whether critically ill patients suffering from heparin resistance generally have low antithrombin III (AT) levels, and if the direct thrombin inhibitor argatroban in that case can be an effective option to achieve prophylactic anticoagulation. argatroban 193-203 serpin family C member 1 Homo sapiens 126-142 25594496-2 2015 The aim of this study was to investigate whether critically ill patients suffering from heparin resistance generally have low antithrombin III (AT) levels, and if the direct thrombin inhibitor argatroban in that case can be an effective option to achieve prophylactic anticoagulation. argatroban 193-203 serpin family C member 1 Homo sapiens 144-146 23329795-0 2013 Emerging applications of argatroban in the management of systemic malignancies: potential benefits besides its primary role as an antithrombin agent. argatroban 25-35 serpin family C member 1 Homo sapiens 130-142 16293985-6 2005 However, the complete loss of thrombin-induced VEGF production upon treatment with argatroban, a derivative of arginine and a potent anticoagulant/antithrombin agent, supports the notion that argatroban serves as a useful therapeutic tool for thrombin-associated pathologic conditions. argatroban 192-202 serpin family C member 1 Homo sapiens 147-159 12096932-5 2002 A small, preliminary clinical trial has suggested that antithrombin therapy with intravenously administered argatroban may be useful in treatment of ICH. argatroban 108-118 serpin family C member 1 Homo sapiens 55-67 14759471-3 2004 In our case, due to the poor reversibility of the antithrombin agents, argatroban was chosen as a heparin substitute due to its short half-life and its anticoagulation assessment using the activated clotting time (ACT). argatroban 71-81 serpin family C member 1 Homo sapiens 50-62 12627673-3 2003 Antithrombin drugs such as argatroban and hirudin are already approved for alternative management of heparin-compromised patients. argatroban 27-37 serpin family C member 1 Homo sapiens 0-12 12361208-1 2002 This is a case series of 5 patients who were treated with the direct antithrombin agents (lepirudin or argatroban) for known or suspected heparin-induced thrombocytopenia thrombosis syndrome (HITTs). argatroban 103-113 serpin family C member 1 Homo sapiens 69-81 12361208-4 2002 These observations provide evidence that the direct antithrombin inhibitors, lepirudin and argatroban, can improve DIC. argatroban 91-101 serpin family C member 1 Homo sapiens 52-64 15162900-10 2004 Direct thrombin inhibitors, such as argatroban, seem to be suitable alternatives for acute anticoagulation in patients with antithrombin deficiency. argatroban 36-46 serpin family C member 1 Homo sapiens 124-136 15171962-1 2004 Argatroban represents the first antithrombin agent that was approved for clinical use. argatroban 0-10 serpin family C member 1 Homo sapiens 32-44 15171962-3 2004 Unlike the other antithrombin drugs, such as hirudins and hirulogs, argatroban is a reversible antithrombin agent and therefore exhibits a considerably different pharmacological profile. argatroban 68-78 serpin family C member 1 Homo sapiens 17-29 15171962-3 2004 Unlike the other antithrombin drugs, such as hirudins and hirulogs, argatroban is a reversible antithrombin agent and therefore exhibits a considerably different pharmacological profile. argatroban 68-78 serpin family C member 1 Homo sapiens 95-107 11065253-2 2000 In our previous study, the antithrombin drug argatroban t ameliorated the neurological exacerbations in a BD patient with antiphospholipid antibody syndrome. argatroban 45-55 serpin family C member 1 Homo sapiens 27-39 12811008-0 2002 Development of argatroban as an anticoagulant and antithrombin agent in Japan. argatroban 15-25 serpin family C member 1 Homo sapiens 50-62 12811008-2 2002 In patients with chronic arterial occlusion, argatroban increased the skin temperature, reduced the size of skin ulcers, and decreased the thrombin-antithrombin complex. argatroban 45-55 serpin family C member 1 Homo sapiens 148-160 12811013-1 2002 Argatroban was the very first antithrombin agent that was approved for clinical use. argatroban 0-10 serpin family C member 1 Homo sapiens 30-42 12811013-3 2002 Unlike other antithrombin drugs, argatroban is a reversible antithrombin agent. argatroban 33-43 serpin family C member 1 Homo sapiens 13-25 12811013-3 2002 Unlike other antithrombin drugs, argatroban is a reversible antithrombin agent. argatroban 33-43 serpin family C member 1 Homo sapiens 60-72 12811013-6 2002 At a comparable ACT (300 s), argatroban produces much stronger inhibition of thrombin generation as measured by F(1.2) and thrombin-antithrombin complex generation. argatroban 29-39 serpin family C member 1 Homo sapiens 132-144 12811013-8 2002 The pharmacological profile of argatroban is unique as this antithrombin drug not only inhibits thrombogenesis but also modulates cellular functions. argatroban 31-41 serpin family C member 1 Homo sapiens 60-72 10726029-9 1999 This was soon followed by experiments with antithrombin drugs such as hirudin and argatroban as replacements for heparin in the HIT-HITT syndrome. argatroban 82-92 serpin family C member 1 Homo sapiens 43-55 10822073-11 2000 While neither drug had any effect on the percutaneous transluminal coronary angioplasty-induced inflammatory response, argatroban may more effectively inhibit the generated thrombin and prevent antithrombin consumption during and after percutaneous transluminal coronary angioplasty. argatroban 119-129 serpin family C member 1 Homo sapiens 194-206 11011802-21 2000 The FDA has approved a recombinant hirudin (Refludan) and a synthetic antithrombin agent, argatroban (Novastan), for this indication. argatroban 90-100 serpin family C member 1 Homo sapiens 70-82 10726036-4 1999 Argatroban represents the first clinically approved antithrombin agent, which was made available in Japan several years ago. argatroban 0-10 serpin family C member 1 Homo sapiens 52-64 9288875-9 1997 The antithrombin activity shows less decrease when argatroban is substituted for heparin. argatroban 51-61 serpin family C member 1 Homo sapiens 4-16 10688418-0 1999 Clinical laboratory monitoring of a synthetic antithrombin agent, argatroban, using high performance liquid chromatography and functional methods. argatroban 66-76 serpin family C member 1 Homo sapiens 46-58 10226408-2 1999 We used an antithrombin agent, argatroban, as an alternative anticoagulant in left heart bypass with the Bio-Medicus centrifugal pump in 7 of 9 recent patients who underwent aortic repair using left heart bypass. argatroban 31-41 serpin family C member 1 Homo sapiens 11-23 9469623-6 1997 For coronary artery disease in patients with deficiency of antithrombin activities attributable to either antithrombin III or heparin cofactor II deficiency, argatroban is effective as an anticoagulant. argatroban 158-168 serpin family C member 1 Homo sapiens 59-71 9469623-6 1997 For coronary artery disease in patients with deficiency of antithrombin activities attributable to either antithrombin III or heparin cofactor II deficiency, argatroban is effective as an anticoagulant. argatroban 158-168 serpin family C member 1 Homo sapiens 106-122 9469625-1 1997 Argatroban is a direct antithrombin agent developed for the first time by Okamoto et al in 1978. argatroban 0-10 serpin family C member 1 Homo sapiens 23-35 9013237-4 1996 Following the debridement under control of diabetes mellitus, antimicrobial agents and argatroban, a newly synthesized antithrombin medicine, were administered. argatroban 87-97 serpin family C member 1 Homo sapiens 119-131 9528269-0 1996 Clinical evaluation of the efficacy of an antithrombin agent "Argatroban" combined with exercise therapy on increase of the skeletal muscle blood flow. argatroban 62-72 serpin family C member 1 Homo sapiens 42-54 8741550-9 1996 Left heart bypass with the Bio-Pump without heparin or with an antithrombin agent, argatroban, was used in recent 6 patients. argatroban 83-93 serpin family C member 1 Homo sapiens 63-75 1920862-9 1991 To reduce the high TAT under the deficient state of ATIII, MD805, a synthetic thrombin inhibitor, was introduced to avoid further consumption of ATIII. argatroban 59-64 serpin family C member 1 Homo sapiens 52-57 8776531-4 1996 We report successful coronary stent implantation in a HITTS patient using the antithrombin agent argatroban. argatroban 97-107 serpin family C member 1 Homo sapiens 78-90 8752690-10 1996 Treatment with antithrombin (argatroban 20mg i.v. argatroban 29-39 serpin family C member 1 Homo sapiens 15-27 7518511-7 1994 The aggregation induced by neuroblastomas and the pheochromocytoma was also suppressed by pretreatment with an antithrombin agent, argatroban, whereas the aggregation induced by Wilms" tumors was not suppressed by this agent. argatroban 131-141 serpin family C member 1 Homo sapiens 111-123 1920862-9 1991 To reduce the high TAT under the deficient state of ATIII, MD805, a synthetic thrombin inhibitor, was introduced to avoid further consumption of ATIII. argatroban 59-64 serpin family C member 1 Homo sapiens 145-150 34381261-13 2021 Conclusion: Argatroban may be more cost-effective during ECMO therapy in patients with low antithrombin III levels without increased risk of adverse events. argatroban 12-22 serpin family C member 1 Homo sapiens 91-107 2264021-0 1990 Effect of a synthetic thrombin-inhibitor MD805 on the reaction between thrombin and plasma antithrombin-III. argatroban 41-46 serpin family C member 1 Homo sapiens 91-107 2264021-4 1990 As a result, MD805 would serve as a protective agent for ATIII from being consumed, in addition to its potent thrombin-inhibitory activity without the aid of ATIII. argatroban 13-18 serpin family C member 1 Homo sapiens 57-62